about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Genen­tech inks $359M deal with Kine­ta; Celldex bat­tered af­ter ADC flops in PhI­Ib

8 years ago
News Briefing

Servi­er buys Shire's on­col­o­gy unit for $2.4B in the run-up to Takeda's fi­nal buy­out of­fer — if it makes one

8 years ago
Pharma

Dal­cor taps new CEO Fouzia Laghris­si-Th­ode as piv­otal PhI­II looms; Kel­ly Mar­tin set­tles in at No­van; Ed­ward Stew­art ...

8 years ago
Peer Review

Penn team spot­lights a pi­lot ovar­i­an can­cer tri­al and sur­vival rates for a per­son­al­ized can­cer vac­cine

8 years ago
R&D
Discovery

For­mer No­vo chair­man Göran An­do joins the board as Tes­sa bags $50M in ad­di­tion­al fund­ing

8 years ago
Financing

Con­tin­u­ing an R&D re­vamp, Glax­o­SmithK­line hands off its rare dis­ease unit to Or­chard Ther­a­peu­tics

8 years ago
R&D

Flush with a $164M raise, Cel­lec­tis ups its bet on CAR-T and gene edit­ing pro­grams

8 years ago
Deals

CymaBay shares soar on tri­al up­date; Lon­za opens mas­sive Texas fa­cil­i­ty ded­i­cat­ed to cell, gene ther­a­pies; In­ovio ...

8 years ago
News Briefing

Am­gen goes back to Rhode Is­land to build its first next-gen man­u­fac­tur­ing site in the US

8 years ago
Pharma

Tap­ping a biotech boom, Chi­na gene edit­ing CRO Bio­cy­to­gen bags $65M round for glob­al ex­pan­sion

8 years ago
Financing
Outsourcing

Ther­a­pix shares rise on ear­ly da­ta of its re­pur­posed cannabi­noid in Tourette syn­drome

8 years ago
R&D

Abeona ap­points new chief as Tim­o­thy Miller moves to CSO; Max­ine Gowen pass­es Treve­na ba­ton to Car­rie Bour­dow; Scott ...

8 years ago
Peer Review

No­vo Nordisk picks up sick­le-cell dis­ease drug in $400M li­cens­ing pact; Sapi­ence teams up with UK re­searcher on ...

8 years ago
News Briefing

EMA hands Italy's Chiesi a win in its long cam­paign to ad­vance new drugs for rare dis­eases

8 years ago
Pharma

With $340M crossover fund, Sofinno­va Part­ners piv­ots to late-stage biotech in­vest­ments while main­tain­ing Eu­ro­pean ...

8 years ago
Financing

As­traZeneca wins pri­or­i­ty re­view sched­ule for leukemia drug; Penn gene ther­a­py up­start grabs $9.29M with Fra­zier's ...

8 years ago
News Briefing

Am­gen vet Marc de Garidel takes the helm at Cor­vidia; Pe­ter Green­leaf lands next CEO job at Cere­cor; Ed­ward Gu­daitis ...

8 years ago
Peer Review

Eye­ing growth in re­gen­er­a­tive med­i­cine, Fu­ji­film spends $800M on two new mem­bers of its CD­MO busi­ness

8 years ago
Deals
Outsourcing

Af­ter a makeover and hir­ing spree, Chi­na's drug agency is romp­ing and stomp­ing on new re­views and ap­provals

8 years ago
China
Pharma

In a bit­ter brawl, Arc­turus de­tails ex-CEO's al­leged mis­con­ducts in law­suit and open let­ter

8 years ago
People
Pharma

Pre­clin­i­cal study shines a light on BET in­hibitors' po­ten­tial to pre­vent obe­si­ty-re­lat­ed can­cer growth

8 years ago
Discovery

Roivant bags Chi­na rights to Nabri­va's an­tibi­ot­ic; Sin­ga­pore’s Aslan Phar­ma lines up an $86M IPO to fund piv­otal ...

8 years ago
News Briefing

Di­rec­tor of di­ver­si­ty and in­clu­sion ar­rives at Mass­Bio; Jerome Jab­bour takes the helm at Mati­nas; Ex-Eli Lil­ly CFO ...

8 years ago
Peer Review

GSK drops out of $20B race for Pfiz­er's con­sumer health unit — shares surge

8 years ago
R&D
First page Previous page 118119120121122123124 Next page Last page
A service from the Financial Times